These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Innovative approaches in drug development. Chang M; Kenley S; Bull J; Chiu YY; Wang W; Wakeford C; McCarthy K J Biopharm Stat; 2007; 17(5):775-89. PubMed ID: 17885865 [TBL] [Abstract][Full Text] [Related]
23. The failure of anxiolytic therapies in early clinical trials: what needs to be done. Stewart AM; Nguyen M; Poudel MK; Warnick JE; Echevarria DJ; Beaton EA; Song C; Kalueff AV Expert Opin Investig Drugs; 2015 Apr; 24(4):543-56. PubMed ID: 25727478 [TBL] [Abstract][Full Text] [Related]
24. Adaptive design clinical trials and trial logistics models in CNS drug development. Wang SJ; Hung HM; O'Neill R Eur Neuropsychopharmacol; 2011 Feb; 21(2):159-66. PubMed ID: 20933373 [TBL] [Abstract][Full Text] [Related]
25. Procedures and methods of benefit assessments for medicines in Germany. Bekkering GE; Kleijnen J Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905 [TBL] [Abstract][Full Text] [Related]
26. Rationale for a non-inferiority clinical trial design focused on subpopulations. Kulkarni PM; Meadows ES; Ahuja S; Muram D; Plouffe L Curr Med Res Opin; 2004 Oct; 20(10):1641-7. PubMed ID: 15462697 [TBL] [Abstract][Full Text] [Related]
27. The cancer and leukemia group B pathology committee at 50. Compton C Clin Cancer Res; 2006 Jun; 12(11 Pt 2):3617s-21s. PubMed ID: 16740795 [TBL] [Abstract][Full Text] [Related]
28. Regulatory and scientific issues in studies to evaluate sexual dysfunction in antidepressant drug trials. Khin NA; Kronstein PD; Yang P; Ishida E; Hung HM; Mathis MV; Unger EF; Temple RJ J Clin Psychiatry; 2015 Aug; 76(8):1060-3. PubMed ID: 26214346 [TBL] [Abstract][Full Text] [Related]
30. Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice. Kinders R; Parchment RE; Ji J; Kummar S; Murgo AJ; Gutierrez M; Collins J; Rubinstein L; Pickeral O; Steinberg SM; Yang S; Hollingshead M; Chen A; Helman L; Wiltrout R; Simpson M; Tomaszewski JE; Doroshow JH Mol Interv; 2007 Dec; 7(6):325-34. PubMed ID: 18199854 [TBL] [Abstract][Full Text] [Related]
31. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
32. The impact of preclinical irreproducibility on drug development. Freedman LP; Gibson MC Clin Pharmacol Ther; 2015 Jan; 97(1):16-8. PubMed ID: 25670378 [TBL] [Abstract][Full Text] [Related]
33. Evaluation of tumor size response metrics to predict survival in oncology clinical trials. Bruno R; Mercier F; Claret L Clin Pharmacol Ther; 2014 Apr; 95(4):386-93. PubMed ID: 24419563 [TBL] [Abstract][Full Text] [Related]
34. Pediatric cardiovascular safety: challenges in drug and device development and clinical application. Bates KE; Vetter VL; Li JS; Cummins S; Aguel F; Almond C; Dubin AM; Elia J; Finkle J; Hausner EA; Joseph F; Karkowsky AM; Killeen M; Lemacks J; Mathis L; McMahon AW; Pinnow E; Rodriguez I; Stockbridge NL; Stockwell M; Tassinari M; Krucoff MW Am Heart J; 2012 Oct; 164(4):481-92. PubMed ID: 23067905 [TBL] [Abstract][Full Text] [Related]
35. American Society of Clinical Oncology policy statement: oversight of clinical research. American Society of Clinical Oncology J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281 [TBL] [Abstract][Full Text] [Related]